IQVIA
Analytics, technology, and clinical research services.
Clinical Consultant
+ Bonus + Incentive Plans
Some travel may be needed, including work at hospitals other than the base location.
About the job
- At least three years of experience with a strong clinical background in the Cardiac Intensive Care Unit, Cardiovascular Intensive Care Unit, Cardiovascular Operating Room, or Catheterization Laboratory is required.
- Significant experience with ventricular medical devices is required, including support for a minimum of 10 cases or patients.
- Provide a minimum of two days of live field support per month and be available for a total of five days per month.
- Availability must include one weekend per month.
- Work weekends, nights, holidays, and weekdays as needed.
- Work at hospitals other than the base location.
- Acquire and demonstrate working knowledge of the company's products and therapies and understand their applications.
- Deliver ventricular medical device education in settings including the Intensive Care Unit, Operating Room, and Catheterization Laboratory.
- Provide ventricular medical device case support, including on-call support.
- Complete proactive rounds for supported patients and provide assistance.
- Collaborate with the Clinical Support Center for additional support as needed.
- Maintain clinical competency in the current product line and patient management, and remain current through continual learning and education.
- Provide case support, patient management, and education to new and existing accounts within an assigned client franchise or region.
- A Registered Nurse or Advanced Practice Provider license is strongly preferred.
- Relevant clinical experience is acceptable in lieu of the preferred Registered Nurse or Advanced Practice Provider license.
- Perfusionist or cardiovascular specialist experience is preferred.
- Cardiac intensive care, cardiovascular intensive care, cardiovascular operating room, or catheterization laboratory experience is required, with cardiovascular intensive care experience highly preferred.
- Some industry experience is preferred but not required.
About the company
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Get referred to IQVIA
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose 8.7%; management raised full-year revenue and EPS guidance.
- R&DS bookings jumped 19.3% in Q2 2026, lifting backlog to $34.2 billion.
- Nineteen of the top 20 pharma firms adopted IQVIA’s AI and analytics stack.
What critics are saying
- Debt reached $15.999 billion on June 30, 2026; refinancing costs rose September 2026.
- AbbVie, Pfizer, and peers can shift trials to Medpace, ICON, or internal platforms.
- If AI claims disappoint regulators or clients, IQVIA’s premium multiples compress fast.
What makes IQVIA unique
- IQVIA’s September 3, 2026 Predictive Clinical Development links data, AI, and trial operations.
- Its Prime and Partner site network and proprietary healthcare data create sticky sponsor workflows.
- The 2016 IMS Health merger gives IQVIA unmatched clinical, commercial, and real-world datasets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%IQVIA MedTech introduces Surgical Collaboration Platform to help scale surgeon education. IQVIA MedTech is highlighting its Surgical Collaboration Platform (SCP), a purpose-built platform designed to help MedTech organizations coordinate and track peer-to-peer surgeon education across the engagement lifecycle. As medical device companies introduce increasingly sophisticated devices, robotic systems, implants and surgical tools, clinician education can play a critical role in supporting technology adoption. However, the infrastructure behind these programs can remain fragmented, with education teams coordinating faculty availability, learner requests, scheduling, credentialing and documentation across spreadsheets, email and disconnected systems. The IQVIA MedTech Surgical Collaboration Platform is designed to bring those activities into a more connected workflow. The platform helps clinicians and education teams manage surgeon requests, credentialing, host-surgeon identification, faculty and site availability, scheduling, documentation, training completion and program reporting. The platform is intended to address an infrastructure challenge that can become increasingly complex as new technologies reach additional surgeons, sites and markets. By creating greater visibility across the education journey, IQVIA aims to help MedTech organizations more effectively coordinate and scale surgeon-to-surgeon education.
IQVIA stock has risen 60.1% over the past six months, outpacing the industry's 4.1% return and the S&P 500's 14% rally. The company's strong performance is driven by accelerating organic growth, with second-quarter 2026 revenue rising 6% year over year. Research & Development Solutions grew 7% organically, whilst the commercial side increased 5%. IQVIA's R&DS net new bookings jumped 19.3% year over year in Q2 2026, producing a book-to-bill ratio of 1.22. Backlog reached $34.2 billion at the end of June. The company has deployed 294 AI agents across 90 use cases. Nineteen of the top 20 pharmaceutical companies have adopted IQVIA's solutions, strengthening its competitive position.
IQVIA Holdings announced its subsidiary IQVIA Inc. priced an offering of $2 billion in senior notes due 2034. The notes will bear interest at 6.375% per annum, with semi-annual payments beginning 15 March 2027, and mature on 15 March 2034. Proceeds will be used to redeem the company's senior 5.000% notes due 2026, repay part of its outstanding revolving credit facility debt, and cover offering fees and expenses. The issuance is expected to close on or about 23 September 2026, subject to customary conditions. IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries, employing approximately 94,000 people across over 100 countries.
HPM presenting at IQVIA Annual Controlled substances & State Regulatory Conference (sept. 16-18). September 4, 2026 Hyman, Phelps & McNamara, P.C.'s Karla Palmer and Andrew Hull will be speaking again at IQVIA's 28th Annual Controlled Substance & State Regulatory Conference in Scottsdale, AZ (Sept. 16-18). As part of a stacked agenda that runs the gamut on controlled substances issues, Ms. Palmer will speak on compliance considerations for compounders, and Mr. Hull will present on how registrants can mitigate risk and preserve reputation during a DEA investigation. Mr. Hull will also be presenting a course with retired DEA Chief Administrative Law Judge John J. Mulrooney, II, a partner at Belanger Rae & Mulrooney, on protecting your rights in DEA administrative actions. Join FDA Law Blog in Scottsdale for what promises to be another educational conference with key thought leaders and industry experts. Register here. Search FDA Law Blog. Subscribe. Never miss a post from FDA Law Blog
IQVIA's Predictive Clinical Development provides sponsors with significant efficiencies to get treatments to market faster. IQVIA introduces an AI-driven clinical development platform that reports sizable time savings from study startup through data cleaning and between trial phases. (Positive) See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 09/03/2026 - 01:15 PM RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical Development is built to eliminate them, accelerating every stage of the development lifecycle with measurable results: * 33% faster study startup * 1.7 times more patients recruited from our AI prioritized and Prime & Partner sites with 42% higher enrollment rates * 50% faster data cleaning * 45%+ reduced time between trial phases IQVIA Predictive Clinical Development pairs IQVIA's proprietary data, deep regulatory expertise and best-in-class Healthcare-grade AI(R) with premier technologies from Anthropic, Amazon Web Services (AWS), Databricks, Microsoft, NVIDIA, Palantir and Snowflake orchestrated to drive agentic workflows. "At a time when every moment matters for patients waiting on new therapies, IQVIA Predictive Clinical Development represents a fundamental shift," said Richard Staub, president of Research and Development Solutions at IQVIA. "We're helping customers make development faster, more predictable and of a higher quality - compressing timelines, accelerating decisions and speeding medicines to market." IQVIA Predictive Clinical Development is enabled by IQVIA's clinical AI capabilities: * Clinical Design & Planning Suite generates predictive insights to inform site selection, prioritizes sites including its Prime and Partner network and operationalizes the recruitment strategy to speed enrollment. * Push Button Start-Up is an integrated and streamlined delivery model that applies standardization, automation and AI-enabled processes to accelerate the time to starting patient enrollment. * Real-time Data Cleaning enables faster, more reliable, higher quality data to make confident decisions during and after a study. It brings clinical data together across multiple sources, drives greater efficiency and enables more rapid database locks. IQVIA is uniquely positioned to change the trajectory of clinical development ultimately closing the gap between scientific discovery to patient care. As IQVIA extends its leadership in AI, new components will continue to expand Predictive Clinical Development across the entire development lifecycle, helping customers move faster with confidence. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Key terms. agentic workflows technical data cleaning technical database locks technical